Neutralization escape of emerging subvariants XBB.1.5/1.9.1 and XBB.2.3 from current therapeutic monoclonal antibodies.

Journal of Medical VirologyVolume 95, Issue 9 e29074 LETTER TO THE EDITOR Neutralization escape of emerging subvariants XBB.1.5/1.9.1 and XBB.2.3 from current therapeutic monoclonal antibodies De Hoe Chye, De Hoe Chye DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, SingaporeSearch for more papers by this authorCharmaine W. Y. Chew, Charmaine W. Y. Chew National Centre for Infectious Diseases, Singapore, SingaporeSearch for more papers by this authorHe Ping Yeo, He Ping Yeo National Centre for Infectious Diseases, Singapore, SingaporeSearch for more papers by this authorPaul A. Tambyah, Paul A. Tambyah Department of Medicine, Infectious Diseases Translational Research Program, Division of Infectious Diseases, National University Hospital, National University of Singapore, Singapore, SingaporeSearch for more papers by this authorBarnaby E. Young, Barnaby E. Young National Centre for Infectious Diseases, Singapore, Singapore Tan Tock Seng Hospital, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorGladys G. Y. Tan, Gladys G. Y. Tan DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, SingaporeSearch for more papers by this authorBoon Huan Tan, Boon Huan Tan DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorShawn Vasoo, Shawn Vasoo National Centre for Infectious Diseases, Singapore, Singapore Tan Tock Seng Hospital, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorConrad E. Z. Chan, Corresponding Author Conrad E. Z. Chan [email protected] orcid.org/0000-0001-5730-7095 DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, Singapore National Centre for Infectious Diseases, Singapore, Singapore Correspondence Conrad E. Z. Chan, Infectious Disease Research Laboratory, National Centre for Infectious Diseases, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore. Email: [email protected]Search for more papers by this author De Hoe Chye, De Hoe Chye DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, SingaporeSearch for more papers by this authorCharmaine W. Y. Chew, Charmaine W. Y. Chew National Centre for Infectious Diseases, Singapore, SingaporeSearch for more papers by this authorHe Ping Yeo, He Ping Yeo National Centre for Infectious Diseases, Singapore, SingaporeSearch for more papers by this authorPaul A. Tambyah, Paul A. Tambyah Department of Medicine, Infectious Diseases Translational Research Program, Division of Infectious Diseases, National University Hospital, National University of Singapore, Singapore, SingaporeSearch for more papers by this authorBarnaby E. Young, Barnaby E. Young National Centre for Infectious Diseases, Singapore, Singapore Tan Tock Seng Hospital, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorGladys G. Y. Tan, Gladys G. Y. Tan DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, SingaporeSearch for more papers by this authorBoon Huan Tan, Boon Huan Tan DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorShawn Vasoo, Shawn Vasoo National Centre for Infectious Diseases, Singapore, Singapore Tan Tock Seng Hospital, Singapore, Singapore Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, SingaporeSearch for more papers by this authorConrad E. Z. Chan, Corresponding Author Conrad E. Z. Chan [email protected] orcid.org/0000-0001-5730-7095 DSO National Laboratories, Defence Medical and Environmental Research Institute, Singapore, Singapore National Centre for Infectious Diseases, Singapore, Singapore Correspondence Conrad E. Z. Chan, Infectious Disease Research Laboratory, National Centre for Infectious Diseases, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore. Email: [email protected]Search for more papers by this author First published: 04 September 2023 https://doi.org/10.1002/jmv.29074Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021; 385(21): 1941-1950. 2Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022; 386(23): 2188-2200. 3Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023; 388(1): 89-91. 4Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis. 2023; 23(6): 655-656. 5Touret F, Giraud E, Bourret J, et al. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. iScience. 2023; 26(4):106413. 6Chan CEZ, Seah SGK, Chye DH, et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLoS One. 2021; 16(6):e0253487. 7Gangavarapu K, Latif AA, Mullen JL, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023; 20(4): 512-522. 8Freed NE, Vlková M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford nanopore rapid barcoding. Biol Methods Protoc. 2020; 5(1):bpaa014. 9Moya J, Temech M, Parra S, et al. Safety, virology, pharmacokinetics, and clinical experience of high-dose intravenous sotrovimab for the treatment of mild to moderate COVID-19: an open-label clinical trial. Open Forum Infect Dis. 2023; 10(7):ofad344. Volume95, Issue9September 2023e29074 ReferencesRelatedInformation